Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
DRUG developer Xenome, once heralded as a potential star for Queensland's biotechnology industry, has suffered a major setback. Plans to develop Xenome's molecule, derived from shellfish venom, to soothe acute post-surgery pain, have been shipwrecked. It failed to meet safety targets set by US regulators, a $20 million blow for Xenome.
Help employers find you! Check out all the jobs and post your resume.
DRUG developer Xenome, once heralded as a potential star for Queensland's biotechnology industry, has suffered a major setback. Plans to develop Xenome's molecule, derived from shellfish venom, to soothe acute post-surgery pain, have been shipwrecked. It failed to meet safety targets set by US regulators, a $20 million blow for Xenome.
Help employers find you! Check out all the jobs and post your resume.
